1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Drugs In Development, 2022, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 3 molecules, respectively.
Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Influenza A Virus, H7N9 Subtype Infections - Overview
- Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development
- AIM ImmunoTech Inc
- AusBio Ltd
- Beijing Tiantan Biological Products Co Ltd
- Celdara Medical LLC
- Cocrystal Pharma Inc
- Codagenix Inc
- CSL Ltd
- EpiVax Inc
- Greffex Inc
- GSK plc
- Hualan Biological Bacterin Co Ltd
- Inovio Pharmaceuticals Inc
- Medicago Inc
- NanoViricides Inc
- New Amsterdam Sciences Inc
- Ology Bioservices Inc
- Pneumagen Ltd
- TaiGen Biotechnology Co Ltd
- Influenza A Virus, H7N9 Subtype Infections - Drug Profiles
- CC-42344 - Drug Profile
- Product Description
- Mechanism Of Action
- CDX-H7N9 - Drug Profile
- Product Description
- Mechanism Of Action
- CMBT-1 - Drug Profile
- Product Description
- Mechanism Of Action
- GSK-3206641A - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] (monovalent) vaccine 1 - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] (monovalent) vaccine 2 - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] (split virion) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strain A/H7N9] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- influenza [strains A/H7N9] (split virion) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- interferon alfa-n3 - Drug Profile
- Product Description
- Mechanism Of Action
- MD-2009 - Drug Profile
- Product Description
- Mechanism Of Action
- MDG-7529 - Drug Profile
- Product Description
- Mechanism Of Action
- NAS-911 - Drug Profile
- Product Description
- Mechanism Of Action
- Neumifil - Drug Profile
- Product Description
- Mechanism Of Action
- NVINF-1 - Drug Profile
- Product Description
- Mechanism Of Action
- NVINF-2 - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Influenza Virus Infections - Drug Profile
- Product Description
- Mechanism Of Action
- TG-1000 - Drug Profile
- Product Description
- Mechanism Of Action
- Influenza A Virus, H7N9 Subtype Infections - Dormant Projects
- Influenza A Virus, H7N9 Subtype Infections - Discontinued Products
- Influenza A Virus, H7N9 Subtype Infections - Product Development Milestones
- Featured News & Press Releases
- Jan 10, 2019: Development and Industrialization Construction Project of Quadrivalent Influenza Vaccine of Hualan Biological Bacterin
- May 23, 2018: Application of Quadrivalent Influenza Vaccine (QIV)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by AIM ImmunoTech Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by AusBio Ltd, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Celdara Medical LLC, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocrystal Pharma Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Codagenix Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by CSL Ltd, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Greffex Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by GSK plc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Hualan Biological Bacterin Co Ltd, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Ology Bioservices Inc, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by Pneumagen Ltd, 2022
- Influenza A Virus, H7N9 Subtype Infections - Pipeline by TaiGen Biotechnology Co Ltd, 2022
- Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, 2022
- Influenza A Virus, H7N9 Subtype Infections - Discontinued Products, 2022
- Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AIM ImmunoTech Inc
- AusBio Ltd
- Beijing Tiantan Biological Products Co Ltd
- Celdara Medical LLC
- Cocrystal Pharma Inc
- Codagenix Inc
- CSL Ltd
- EpiVax Inc
- Greffex Inc
- GSK plc
- Hualan Biological Bacterin Co Ltd
- Inovio Pharmaceuticals Inc
- Medicago Inc
- NanoViricides Inc
- New Amsterdam Sciences Inc
- Ology Bioservices Inc
- Pneumagen Ltd
- TaiGen Biotechnology Co Ltd
